Salspera
Phase 2Saltikva is our lead program in patients with Stage 4, metastatic pancreatic cancer. The Phase 2 results showed that Saltikva was able to reduce tumor markers, tumor burden, and increase Progression Free Survival and Overall Survival when administered with modified FOLFIRINOX. No serious adverse reactions were caused by Saltikva in the clinical study.
About
Saltikva is our lead program in patients with Stage 4, metastatic pancreatic cancer. The Phase 2 results showed that Saltikva was able to reduce tumor markers, tumor burden, and increase Progression Free Survival and Overall Survival when administered with modified FOLFIRINOX. No serious adverse reactions were caused by Saltikva in the clinical study.
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile